Runaway demand for AI data centers, highlighted by Nvidia’s US$5.7t market cap milestone, shows how quickly capital is chasing tools that can crunch medical data, scan images, and support virtual care at global scale. That same engine is starting to reshape healthcare. Missing the early phase may mean missing where a lot of value could potentially accrue. This article breaks down three AI healthcare stocks from the screener that are worth watching.
The three stocks covered below are only a sample from the idea, with the full screen surfacing 32 more AI healthcare companies that carry similarly compelling stories the article does not touch. If you want to identify and analyze the highest conviction setups across that wider group, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener
Pfizer is a global biopharma giant that discovers and sells medicines across vaccines, oncology, rare diseases, immunology, and more. It is also working with Boltz on biomolecular AI models that could reshape how future drugs are found and developed. The group generated about US$63.7b from its Global Biopharmaceuticals Business and segment adjustments, and is valued at roughly US$160.3b.
Pfizer’s push into biomolecular AI puts hard science behind the screener thesis, since investors are not just looking at digital tools around the edges of care, but at a drug maker trying to rewire how molecules are designed and advanced through the lab.
“AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription.”
What happens to Pfizer’s long run profitability if one quietly building AI program changes how quickly its best new therapies reach patients?
That kind of step change is exactly what the full narrative for Pfizer unpacks, highlighting where accelerating AI drug design, capital allocation, and real execution risks could reshape Pfizer’s long term profile.
NYSE:PFE Earnings & Revenue History as at Oct 2026
Medtronic is a US$110.6b medical device heavyweight that treats cardiac, neurological, and surgical conditions, with most revenue coming from Cardiovascular at US$14.6b, then Neuroscience at US$10.5b and Medical Surgical at US$9.0b, where its AI surgical video and analytics platform lives.
Where Pfizer experiments with AI in molecule design, Medtronic is wiring intelligence into the operating room itself, using AI to interpret surgical video, tighten workflows, and support decisions during procedures in real time.
“The separation of the MiniMed diabetes business, which carries structurally lower margins and higher R&D intensity, together with SKU rationalization and design to cost programs, is expected to move Medtronic toward higher gross and operating margins and support faster EPS growth once the spin off is fully reflected in reported results.”
What that could mean for Medtronic’s earnings profile depends on how a single quiet shift in its procedure mix and AI adoption ultimately plays out.
That hinge point is exactly where the full narrative for Medtronic zooms in, mapping how AI, mix shifts and capital choices could be accelerating or quietly masking Medtronic’s next leg of earnings power.
NYSE:MDT Revenue & Expenses Breakdown as at Oct 2026
Stryker is a US$104.7b medical technology group that sells surgical tools, neurotechnology and orthopaedic implants, with MedSurg and Neurotechnology generating about US$16.1b and Orthopaedics about US$9.7b. Its Mako smart robotics and AI-assisted virtual care platform link directly to the screener’s AI healthcare theme.
Stryker’s role in AI-assisted surgery and connected care matters here because its robotics, navigation and virtual care tools plug directly into how hospitals try to raise accuracy, cut complications and stretch scarce staff across more procedures.
“Continued strength in hospital capital spending, reflected in an elevated order book, record Mako sales, and solid demand for beds and Smart Care offerings, points to ongoing uptake of higher value equipment that can support both top line growth and mix driven margin improvement.”
What happens to Stryker’s earnings power if a single assumption about how quickly surgeons adopt its AI-guided tools proves either too cautious or too optimistic?
If that adoption curve is what really moves Stryker’s story, the full narrative for Stryker shows where earnings power could be quietly accelerating or stalling next.
NYSE:SYK Earnings & Revenue Growth as at Oct 2026 Seeking Fresh Alternatives Before They Fly
Fresh breakout stories rarely stay under the radar for long. Once momentum is caught by the crowd, clean entry points start dropping away. Scan these ideas while it matters and get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com